drugset / Trial / NCT00283426

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

NCT00283426 ↗

Phase 1 Terminated 10 enrolled Biotec Pharmacon ASA
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether soluble beta-1,3/1,6-glucan is an effective and safe treatment of thermal burns and non-injured skin where skin grafts are harvested. Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities improve wound healing of thermal burns and non-injured skin where skin grafts are harvested.

Timeline

Start
2006-01
Primary completion
—
Completion
2007-03

Outcome

Outcome not reported

Stopped (Enrollment): “Slow patient recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Soluble beta-1,3/1,6-glucan Unknown — —

Indications

No indication recorded.